$331 Million is the total value of RTW INVESTMENTS, LP's 36 reported holdings in Q3 2016. The portfolio turnover from Q2 2016 to Q3 2016 was 47.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LJPC | Sell | La Jolla Pharmaceutical Co | $27,838,000 | +47.9% | 1,170,151 | -0.5% | 8.41% | +30.9% |
| INCY | Sell | Incyte Corp | $18,024,000 | -42.5% | 191,151 | -51.3% | 5.45% | -49.2% |
| ACHN | Sell | Achillion Pharmaceuticals Inc | $17,891,000 | -5.4% | 2,208,749 | -8.9% | 5.41% | -16.3% |
| BLUE | Sell | bluebird bio Inc | $5,947,000 | -77.6% | 87,734 | -85.7% | 1.80% | -80.1% |
| CLDX | Sell | Celldex Therapeutics Inc | $5,022,000 | -9.5% | 1,243,164 | -1.7% | 1.52% | -19.9% |
| OMER | Sell | Omeros Corp | $4,274,000 | -22.9% | 383,012 | -27.3% | 1.29% | -31.7% |
| RGNX | Sell | Regenxbio Inc | $3,345,000 | +72.2% | 238,740 | -1.7% | 1.01% | +52.5% |
| FPRX | Sell | Five Prime Therapeutics Inc | $2,312,000 | +25.1% | 44,044 | -1.5% | 0.70% | +10.8% |
| GBT | Sell | Global Blood Therapeutics Inc | $2,206,000 | +36.8% | 95,714 | -1.5% | 0.67% | +21.1% |
| MRTX | Sell | Mirati Therapeutics Inc | $854,000 | +19.3% | 129,129 | -1.5% | 0.26% | +5.3% |
| MDRX | Exit | Allscripts Healthcare Solutions Inc | $0 | – | -48,000 | -100.0% | -0.21% | – |
| SRTSU | Exit | Sensus Healthcare Incunit 99/99/9999 | $0 | – | -155,000 | -100.0% | -0.34% | – |
| CYTR | Exit | CytRx Corp | $0 | – | -466,200 | -100.0% | -0.36% | – |
| AXDX | Exit | Accelerate Diagnostics Inc | $0 | – | -74,843 | -100.0% | -0.37% | – |
| ICPT | Exit | Intercept Pharmaceuticals Inc | $0 | – | -39,500 | -100.0% | -1.93% | – |
| TLT | Exit | iShares 20+ Year Treasury Bond ETF20 yr tr bd etf | $0 | – | -45,000 | -100.0% | -2.14% | – |
| ATRA | Exit | Atara Biotherapeutics Inc. | $0 | – | -465,874 | -100.0% | -3.58% | – |
| SSRG | Exit | Symmetry Surgical Inc | $0 | – | -922,215 | -100.0% | -4.14% | – |
| KITE | Exit | Kite Pharma Inc | $0 | – | -285,518 | -100.0% | -4.88% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2016-11-18
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS INC | 36 | Q3 2023 | 19.7% |
| MASIMO CORP | 32 | Q3 2023 | 5.8% |
| LA JOLLA PHARMACEUTICAL CO | 31 | Q2 2022 | 9.7% |
| REGENXBIO INC | 30 | Q4 2022 | 10.8% |
| AGENUS INC | 29 | Q2 2022 | 9.0% |
| PTC THERAPEUTICS INC | 28 | Q3 2023 | 12.8% |
| DICERNA PHARMACEUTICALS INC | 28 | Q3 2021 | 10.8% |
| MIRATI THERAPEUTICS INC | 26 | Q3 2023 | 6.2% |
| ARGENX SE | 26 | Q3 2023 | 5.3% |
| VERICEL CORP | 24 | Q3 2023 | 3.9% |
View RTW INVESTMENTS, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. | September 19, 2023 | 18,188,457 | - |
| ALLURION TECHNOLOGIES, INC. | August 11, 2023 | 3,457,707 | 7.4% |
| Orchestra BioMed Holdings, Inc. | May 05, 2023 | 5,620,645 | 15.7% |
| Renovacor, Inc.Sold out | April 05, 2023 | 0 | - |
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Aptevo Therapeutics Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ASLAN Pharmaceuticals LtdSold out | February 14, 2023 | 0 | 0.0% |
| Athira Pharma, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| BELLUS Health Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Clearside Biomedical, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
View RTW INVESTMENTS, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13D/A | 2024-04-17 |
| SC 13D/A | 2024-03-01 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View RTW INVESTMENTS, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.